Proactive Investors - Run By Investors For Investors

Scancell Holdings PLC to present at World Vaccine Congress

Dr Peter Brown, Scancell's clinical and scientific consultant on Immunotherapeutics, will give a presentation entitled: "SCIB1 ImmunoBody stimulates a potent T cell response that eradicates tumours and prevents recurrence".
Scancell Holdings PLC to present at World Vaccine Congress
In patients with resected (excised) disease there is increasing evidence to suggest that SCIB1 may delay or prevent disease recurrence.

Scancell Holdings PLC's (LON:SCLP) Dr Peter Brown is to present an update on the company's SCIB1 ImmunoBody cancer vaccine at this year's World Vaccine Congress.

The presentation, entitled: "SCIB1 ImmunoBody stimulates a potent T cell response that eradicates tumours and prevents recurrence", will be presented on Wednesday 30 March 2016 at 11.40am EDT at the congress in Washington DC.

Dr Brown is Scancell's clinical and scientific consultant on Immunotherapeutics.

Scancell's first ImmunoBody, SCIB1, is currently being evaluated in a Phase 1/2 clinical trial in patients with Stage III/IV melanoma. The latest data suggests that SCIB1 may have the potential to significantly extend survival times in patients, especially in those with resected disease. 

Scancell is in the process of preparing a final clinical study report. A Phase 2 checkpoint inhibitor combination study of SCIB1 in melanoma is due to commence in 2017.

"We are delighted to be presenting an update on SCIB1 at the World Vaccine Congress, alongside some of the most distinguished companies in the immunotherapy field,” said Richard Goodfellow, joint chief executive officer of Scancell.

“Funds from the recently announced  placing and the pending open offer will be used to further progress our ImmunoBody and Moditope platforms, including helping to fund our expanded SCIB1 clinical trial programme, which will be led by a team of leading US specialists," he added.

Why Invest In Scancell Holdings Plc? Read More Here

Register here to be notified of future SCLP Company articles
View full SCLP profile

Scancell Holdings Plc Timeline

August 22 2016

Related Articles

July 13 2016
Updating investors, the company said turnover will be around £48.5mln, representing a rise of 12%, or 19% once the figure is adjusted for currency movements.
Pills and the EU stars
July 19 2016
Alliance's swoop for Sinclair Healthcare Products in December helped it rack up first-half sales of £46.4mln
April 05 2016
If the market worked as perfectly as its more rabid advocates insist, we wouldn’t have attractive anomalies such as Synairgen..

© Proactive Investors 2016

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.